itraconazol
J - Antiinfectives For Systemic Use -> J02 - Antimycotics For Systemic Use -> J02A - Antimycotics For Systemic Use -> J02AC - Triazole Derivatives -> J02AC02 - Itraconazole
Administration category:
Free
Medicine group:
antifungal
Brand name:
Trisporal
Safety margins
Weight | ROA | Dosage |
---|---|---|
ROA: po |
Dosage: min. 100mg 1 dd to max. 200mg 2 dd |
|
ROA: iv |
Dosage: min. 100mg 1 dd to max. 200mg 2 dd |
Kidney function
ROA | GFR | Dosage | Interval | Comments |
---|---|---|---|---|
ROA: iv | ||||
GFR: <50 |
Dosage: Geen dosisaanpassing nodig |
Renal elimination:
0%
Dosage:
independent on kidney function
Renal function-replacement therapy
CAPD: Geen dosisaanpassing nodig
Hemo dialysis: Geen dosisaanpassing nodig
CAV / VVHD: Geen dosisaanpassing nodig
Interactions
Interaction with (ATC): | Interaction with: | Expected effect: |
---|---|---|
Interaction with (ATC): A02BC - Proton Pump Inhibitors |
Interaction with: geldt niet voor drank |
Expected effect: verlaging absorptie itraconazol |
Interaction with (ATC): A02BA - H2-Receptor Antagonists |
Interaction with: geldt niet voor drank |
Expected effect: verlaging absorptie itraconazol |
Interaction with (ATC): A03FA02 - Cisapride |
Interaction with: |
Expected effect: toename cardiotoxiciteit cisapride |
Interaction with (ATC): R06AX12 - Terfenadine |
Interaction with: |
Expected effect: toename cardiotoxiciteit terfenadrine |
Interaction with (ATC): J01FA09 - Clarithromycin |
Interaction with: |
Expected effect: verhoging plasmaconcentratie itraconazol |
Interaction with (ATC): C01AA05 - Digoxin |
Interaction with: |
Expected effect: verhoging plasmaconcentratie digoxine |
Interaction with (ATC): N03AB02 - Phenytoin |
Interaction with: |
Expected effect: sterke verlaging itraconazol plasmaconcentratie |
Interaction with (ATC): J05AG01 - Nevirapine |
Interaction with: |
Expected effect: verhoging plasmaconcentratie nevirapine en itraconazol |
Interaction with (ATC): J05AE - Protease Inhibitors |
Interaction with: |
Expected effect: verhoging plasmaconcentratie proteaseremmers |
Interaction with (ATC): J04AB02 - Rifampicin |
Interaction with: |
Expected effect: verlaging plasmaconcentratie itraconazol |
Interaction with (ATC): J04AB04 - Rifabutin |
Interaction with: |
Expected effect: verlaging plasmaconcentratie itraconazol |
Interaction with (ATC): L04AD01 - Ciclosporin |
Interaction with: |
Expected effect: verhoging ciclosporineconcentratie in volbloed |
Interaction with (ATC): L04AD02 - Tacrolimus |
Interaction with: |
Expected effect: verhoging plasmaconcentratie tacrolimus |
Interaction with (ATC): L04AA10 - Sirolimus |
Interaction with: |
Expected effect: verhoging plasmaconcentratie sirolimus |
Interaction with (ATC): B01AA - Vitamin K Antagonists |
Interaction with: |
Expected effect: toename werking orale anticoagulantia |
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
For individual advice, consult an expert on site.
Metadata
Swab vid: M-500520.1
Updated: 09/09/2021 - 14:32
Status: Published